In a report issued on June 8, Kerry Holford from Berenberg Bank maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $345.00. The company’s shares closed last Tuesday at $290.79.
Holford has an average return of 9.1% when recommending Eli Lilly & Co.
According to TipRanks.com, Holford is ranked #1734 out of 7889 analysts.
Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $324.64, representing a 12.3% upside. In a report issued on June 1, J.P. Morgan also maintained a Buy rating on the stock with a $355.00 price target.
The company has a one-year high of $324.08 and a one-year low of $217.00. Currently, Eli Lilly & Co has an average volume of 2.97M.
Based on the recent corporate insider activity of 135 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
Read More on LLY:
- Guggenheim Thinks Gap’s Stock is Going to Recover
- H.C. Wainwright Thinks Imago BioSciences’ Stock is Going to Recover
- H.C. Wainwright Keeps a Buy Rating on PharmaTher Holdings Ltd (PHRRF)
- Opthea Limited (CKDXF) Receives a Buy from Goldman Sachs
- Nanosonics Limited (NNCSF) Receives a Sell from Goldman Sachs